Skip to content
Screener

Zymeworks ZYME Q4 2025 Annual earnings

Reported March 2, 2026 · Before market open

Revenue$2.5MMiss by $16.7M
EPS-$0.55Miss by $0.20
Revenue estimate$19.2M
EPS estimate-$0.35

Next report

Nov 5, 2026 (In 3 weeks)
Revenue estimate$227.4M
EPS estimate$2.29

Financials

Q4 2025

Income statement

See full
Revenue$2.5M-91.9%
Operating income-$44.2M-98.7%
Net income-$41.2M-75.3%
EPS (diluted)-$0.55-71.9%

Balance sheet

See full
Cash & equivalents$41.2M-37.7%
Total debt$18.3M-1.6%
Total equity$268.5M-20.7%
Total assets$346.5M-25.2%

Cash flow

See full
Operating cash flow-$10.3M+75.3%
CapEx$581.0K+85.0%
Free cash flow-$10.8M+74.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.99B+96.9%
Enterprise value$1.96B+104%
P/S18.7×+5.5×

Profitability

See full
Operating margin-87.3%-29.6pp
Net margin-76.6%-26.3pp
FCF margin-32.6%-14.3pp

Returns & leverage

See full
Return on equity-26.7%-3.0pp
Debt / equity0.1×0.0×
Current ratio5.9×+2.5×

Segments

By product

See full
Royalties$898.0K+798%
Drug supply for ongoing studies$780.0K-79.3%
Development support payments$296.0K—
Other drug supply--100%

FAQ

When did Zymeworks report Q4 2025 earnings?
Zymeworks (ZYME) reported Q4 2025 earnings on March 2, 2026 before market open.
What were Zymeworks's Q4 2025 revenue and EPS?
Zymeworks reported revenue of $2.5M and eps of $-0.55 for Q4 2025.
Did Zymeworks beat estimates in Q4 2025?
Revenue missed the consensus estimate of $19.2M by $16.7M. EPS missed the consensus estimate of $-0.35 by $0.20.
How did Zymeworks's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 91.9% from $31.0M a year earlier and eps declined 77.4% from $-0.31.
Where can I find Zymeworks's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001937653-26-000013) and the 10-K periodic report (0001937653-26-000015) directly on SEC EDGAR. The filing index links above go to sec.gov.